Merck KGaA chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 48.20
Dividend & YieldN/A£ (N/A)
Beta 0.68
Market capitalization N/A
Operating cash flow 4.2B
ESG Scores 21.3

Company description

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat neurology and immunology, oncology, fertility, and cardiology metabolism and endocrinology. The company also supplies products, tools, and services for research laboratories, pharma and biotech production, and industrial and testing laboratories. In addition, it offers material for integrated circuits, liquid crystals, organic light-emitting diodes, photoresists, smart antenna, and liquid crystal glazing solutions, as well as effect pigments for use in automotive coatings, cosmetics, industrial, and plastic applications. It has strategic alliances with Pfizer Inc.; agreement with Novartis AG; and license agreements with Debiopharm International SA and MoonLake Immunotherapeutics AG. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.

Sector: - Industry:

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 104M 201M 7M 433M
Total Cashflows From Investing Activities 2.19B -6.15B -1.34B -1.58B
Net Borrowings -2.06B 2.59B -835M -1.75B
Total Cash From Financing Activities -2.83B 1.9B -1.52B -2.5B
Change To Operating Activities -89M -238M -233M 75M
Issuance Of Stock
Net Income 3.37B 1.32B 1.99B 3.06B
Change In Cash 1.58B -1.39B 575M 543M
Effect Of Exchange Rate -5M 5M -40M 9M
Total Cash From Operating Activities 2.22B 2.86B 3.48B 4.62B
Depreciation 1.7B 1.82B 1.67B 1.62B
Change To Account Receivables -109M -47M -84M -310M
Other Cashflows From Financing Activities -14M -12M -7M -9M
Change To Netincome -2.64B 42M 130M 128M
Capital Expenditures -910M -813M -1.41B -1.07B

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 2.23B 2.24B 2.26B 2.4B
Income Before Tax 1.46B 1.74B 2.63B 3.92B
Net Income 3.37B 1.32B 1.99B 3.06B
Selling General Administrative 5.49B 5.68B 5.29B 5.47B
Gross Profit 9.49B 10.2B 10.75B 12.36B
Ebit 1.98B 2.55B 3.07B 4.35B
Operating Income 1.98B 2.55B 3.07B 4.35B
Interest Expense -268M -403M -328M -244M
Income Tax Expense 368M 440M 637M 859M
Total Revenue 14.84B 16.15B 17.53B 19.69B
Cost Of Revenue 5.34B 5.95B 6.78B 7.33B
Total Other Income ExpenseNet -517M -818M -440M -429M
Net Income From Continuing Ops 1.09B 1.29B 1.99B 3.06B
Net Income Applicable To Common Shares 3.37B 1.32B 1.99B 3.06B

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 19.66B 25.89B 24.78B 23.95B
Total Stockholder Equity 17.2B 17.84B 16.95B 21.34B
Other Current Liabilities 3.56B 4.76B 4.52B 4.8B
Total Assets 36.89B 43.81B 41.8B 45.36B
Common Stock 565M 565M 565M 565M
Other Current Assets 120M 124M 189M 157M
Retained Earnings 12.53B 13.13B 14.45B 16.61B
Treasury Stock 296M 329M -1.89B 349M
Cash 2.17B 781M 1.35B 1.9B
Total Current Liabilities 8.52B 11.84B 9.23B 10.43B
Other Stockholder Equity 296M 329M -1.89B 349M
Property, Plant, and Equipment 4.81B 6.19B 6.42B 7.22B
Total Current Assets 9.24B 9B 9.28B 10.98B
Net Tangible Assets -3.8B -8.49B -6.67B -3.28B
Net Receivables 4.06B 4.57B 4.28B 4.77B
Accounts Payable 1.77B 1.38B 1.09B 1.54B


Insider Transactions

Here are the insider transactions of stock shares related to Merck KGaA:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Merck KGaA. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Merck KGaA

Here is the result of two systematic investment strategies applied to Merck KGaA. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Merck KGaA

The following chart shows the equity curve of the two systematic investment strategies applied to Merck KGaA:

Merck KGaA automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 0% on the backtest period.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

0.0 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Merck KGaA

This is the result of two momentum investment strategies applied to Merck KGaA. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Merck KGaA

The following chart shows all the entries opened by the momentum investment system on Merck KGaA:

Merck KGaA momentum entries
  • The first momentum investment strategy would give 9.22% of return on Merck KGaA. That represents 17.98£ of latent gain with 195.05£ of employed capital.
  • The second momentum investment strategy would give 0% of return on Merck KGaA. That represents 0.0£ of latent gain with 0.0£ of employed capital.
Performance at glance (1Q Momentum)

Performance

9.22 %

Latent gain

17.98 £

Invested capital

195.05 £

Annualized return

-0.0 %
Performance at glance (2Q Momentum)

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Momentum equity curve on Merck KGaA

The following chart shows the equity curve of the two momentum strategies applied to Merck KGaA:

Merck KGaA momentum equity

Note: the dividends potentially given by Merck KGaA are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Merck KGaA

The following chart shows the employed capital evolution of the two momentum strategies on Merck KGaA since the beginning:

Merck KGaA

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250£, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000£.


Buy the dip strategy result on Merck KGaA

Buy the dip entry openings on Merck KGaA

Merck KGaA

The performance achieved by the robo-advisor on Merck KGaA is 0%. That represents 0.0$ of latent gain with 0.0£ of employed capital. The following chart shows Merck KGaA stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Merck KGaA, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Equity curve of the strategy applied to Merck KGaA

The following chart shows the result of the investment strategy applied to Merck KGaA:

Merck KGaA

Note: the dividends potentially given by Merck KGaA are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Merck KGaA

The following chart shows the employed capital evolution since the beginning of the investment strategy on Merck KGaA:

Merck KGaA

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Merck KGaA

In this section, I will compare the three previous investment strategies applied to Merck KGaA.

Equity curve comparison on Merck KGaA

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Merck KGaA investment strategy comparison

Employed capital comparison on Merck KGaA

Merck KGaA investment comparison

Performance comparison on Merck KGaA

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 0% 0.0£ 0.0£ 0.0%
Momentum 1 quarter 9.22% 17.98£ 195.05£ 230.5%
Momentum 2 quarters 0% 0.0£ 0.0£ -0.0%
Non-directional 0% 0.0£ 0.0£ -0.0%
Annualized return comparison

Automatic investment

0.0 %

Momentum 1Q

-0.0 %

Momentum 2Q

-0.0 %

Non-directional

-0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Merck KGaA:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between Merck KGaA and the other stocks. There may be false positives or some missing correlated stocks. If the price of Merck KGaA does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Merck KGaA
Country Germany
City Darmstadt
Address Frankfurter Strasse 250
Phone 49 6151 72 0
Website www.merckgroup.com
FullTime employees 62770
Industry
Sector
Exchange XLON
Ticker 0O14.XLON
Market www.londonstockexchange.com

Merck KGaA ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 2.6
Peer Environment Performance 2.0330864197531
Environment Percentile unknown
Palm Oil no
Nuclear no
Fur Leather no
GMO no
Coal no
Pesticides no
Animal Testing yes

Social scores

Social ESG Factors Scores
Social Score 10.0
Peer Social Performance 14.299012345679
Social Percentile unknown
Highest Controversy 2
Peer Highest Controversy Performance 1.8780487804878
Adult no
Gambling no
Alcoholic no
Tobacco no
Catholic yes
Controversial Weapons no
Small Arms no
Military Contract no
Peer Count yes

Related Controversy: Employee Incidents


Governance scores

Governance ESG Factors Scores
Governance Score 8.6
Peer Governance Performance 8.8141975308642
Governance Percentile unknown

ESG at glance
Total ESG Scores: 21.3
Environment Score: 2.6
Social Score: 10.0
Governance Score: 8.6

ESG Performance: AVG_PERF

Peer Group: Pharmaceuticals

Peer Esg Score Performance: 25.306097560976

Rating Year: 2022

Rating Month: 8

Max Age: 86400

Percentile: 30